Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT06501066

Mesenchymal Stem Cells for Frailty Syndrome

A Two-part, Phase I/II, Randomized, Single-blind Study to Evaluate the Efficacy and Safety of UMC119-06-05 in Older Adults With Pre-frailty & Frailty

Sponsor: Meribank Biotech Co., Ltd.

Conditions Pathologic Processes

Interventions umbilical cord mesenchymal stem cells

Updated 3 times since 2024 Last updated: Jul 11, 2024 Started: Jun 3, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Pathologic Processes and is currently ongoing. Meribank Biotech Co., Ltd. leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Meribank Biotech Co., Ltd.

Data source: Meribank Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan